HomeFEATURED

SciBase and Schweiger Dermatology Group Partner to Advance Skin Cancer Detection at Select New Jersey Locations

What To Know

  • In addition to the early detection benefits for patients, the partnership means clinicians at Schweiger Dermatology Group’s Freehold and Verona, New Jersey offices will have access to state-of-the-art melanoma detection technology.
  • “We are excited to integrate the Nevisense test during routine skin exams in our Freehold and Verona, New Jersey offices and offer our patients the latest technology for the earliest possible detection of melanoma.

SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Schweiger Dermatology group (“SDG”) to pilot Nevisense in their Freehold, NJ office. Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania, and Connecticut. The agreement will provide Schweiger Dermatology Group’s Freehold, New Jersey practice with Nevisense, the only FDA approved test for early melanoma detection at point-of-care.

“We are excited to integrate the Nevisense test during routine skin exams in our Freehold and Verona, New Jersey offices and offer our patients the latest technology for the earliest possible detection of melanoma. Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate. Early testing and treatment are critical for improving survival rates. Providing our patients with the most advanced technology further supports our commitment to delivering the best care to our patients,” said Dr. Jason H. Miller, Medical Director for New Jersey and Long Island for Schweiger Dermatology Group.

“We are very pleased to announce our collaboration with Schweiger Dermatology Group. In addition to the early detection benefits for patients, the partnership means clinicians at Schweiger Dermatology Group’s Freehold and Verona, New Jersey offices will have access to state-of-the-art melanoma detection technology. For SciBase, we establish a further partner that helps introduce Nevisense to US payers,” said Simon Grant, Chief Executive Officer of SciBase.

SourceSciBase
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Discover Reeva FT: Revolutionizing Wound Covering for Healthcare Pros

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.

Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).

Polymer Medical Launches in Western New York by Two Industry Leaders

“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.

Summus Medical Laser | Launches Real-World Evidence Program

The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.

Revolutionary Breakthrough: New Antimicrobial Wound Dressings Unveiled at EWMA 2024

Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.

© Medical Device News Magazine 2024